COMPANY

South Rampart Pharma, LLC

HQ: San Francisco, CA source · southrampartpharma.com ↗ · Southeast

Keywords: neuropathic pain chronic pain SRP-3D (diethylamide)

Location: San Francisco, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

Timeline

Dec 30, 2021 Trial start Phase 1: Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA) source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT05484414	Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)	Phase 1	Completed	Dec 30, 2021	Nov 6, 2023 (actual)

Annual award amounts. Total $2.3M.

Sep 21, 2023 NIH award 2SB1NS119103-04 FY2023: $399,539 awarded for that fiscal year; activity SB1 (SBIR); PI NAISMITH, ROBERT; recipient as written: SOUTH RAMPART PHARMA, LLC, NEW ORLEANS, LA. Novel non-narcotic analgesic for ac source ↗
Aug 30, 2022 NIH award 5R42NS119103-03 FY2022: $840,427 awarded for that fiscal year; activity R42 (STTR); PI BAZAN, NICOLAS G.; recipient as written: SOUTH RAMPART PHARMA, LLC, NEW ORLEANS, LA. Novel non-narcotic analgesic for a source ↗
Sep 1, 2021 NIH award 4R42NS119103-02 FY2021: $840,427 awarded for that fiscal year; activity R42 (STTR); PI BAZAN, NICOLAS G.; recipient as written: SOUTH RAMPART PHARMA, LLC, NEW ORLEANS, LA. Novel non-narcotic analgesic for a source ↗
Sep 21, 2020 NIH award 1R42NS119103-01A1 FY2020: $252,125 awarded for that fiscal year; activity R42 (STTR); PI BAZAN, NICOLAS G.; recipient as written: SOUTH RAMPART PHARMA, LLC, NEW ORLEANS, LA. Novel non-narcotic analgesic for source ↗